Respreeza (human alpha-1-proteinase inhibitor): Sterility issue with the infusion device co-packed with Respreeza 4.000 mg and 5.000 mg
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
Medicine name |
Respreeza
|
Active substance |
Human alpha1-proteinase inhibitor
|
Therapeutic area (MeSH) |
|
Procedure number |
EMEA/H/C/002739
|
DHPC type |
Medicine shortage
|
Human ATC code |
B02AB02
|
Dissemination date |
26/03/2021
|